Takeda Sues 3 Rivals Over Planned Heartburn Drug Generics
Law360, New York (May 30, 2013, 1:46 PM EDT) -- Takeda Pharmaceutical Co. Ltd. on Wednesday sued Sandoz Inc. and two other rivals in California federal court, accusing their planned generic versions of acid reflux treatment Dexilant of infringing a patent for the drug.
According to Takeda, abbreviated new drug applications filed by generic drugmakers Sandoz, Impax Laboratories Inc. and TWi Pharmaceuticals Inc., seeking U.S. Food and Drug Administration approval to make and sell generic dexlansoprazole delayed-release capsules in 30 and 60 milligram dosage strengths, had infringed on U.S. Patent Number 8,173,158.
"Unless [the drugmakers are] enjoined by the court, plaintiffs will be substantially and irreparably damaged and harmed by [the]...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!